This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Balkwill, F. R. Articles by Fiers, W. Search for Related Content PubMed PubMed Citation Articles by Balkwill, F. R. Articles by Fiers, W.

Therapeutic Potential of Tumor Necrosis Factor- and -Interferon in Experimental Human Ovarian Cancer

Imperial Cancer Research Fund, Lincoln's Inn Fields, London, WC2A 3PX, United Kingdom [F. R. B., B. G. W., E. M.], and Laboratory of Molecular Biology, University of Ghent, Ledeganckstratte 35, B-9000, Ghent, Belgium [W. F.]

We have studied the activity of recombinant human -interferon and recombinant human tumor necrosis factor against four human ovarian cancer i.p. xenografts OS, LA, HN, and DO derived from primary tumor material. In the OS xenograft all control mice died by 42 days and therapy starting 7 days after tumor cell injection with 5 x 10⁴ units recombinant human -interferon or 1 µg recombinant human tumor necrosis factor alone had no significant effect on cumulative survival in three separate experiments. However, a combination of the two agents resulted in 85% cumulative survival at 150 days. This combination therapy also significantly increased survival of mice treated as late as 21 days after tumor cell injection. In the LA xenograft (where control mice were all dead by 23 days) therapy with either agent alone, or a combination, more than doubled survival time of mice. In the HN xenograft all control mice were dead at 22 days whereas either therapy alone or in combination gave +85% cumulative survival at 100 days. In a fourth xenograft, DO, survival of mice in the combination therapy group was significantly increased. Thus these two biological therapies, alone or in combination, show significant activity against human ovarian cancer cells.

¹ To whom requests for reprints should be addressed.

Received 3/ 3/87. Revised 5/29/87. Accepted 6/16/87.

This article has been cited by other articles:

				C. Van Themsche, L. Lafontaine, and E. Asselin X-Linked Inhibitor of Apoptosis Protein Levels and Protein Kinase C Activity Regulate the Sensitivity of Human Endometrial Carcinoma Cells to Tumor Necrosis Factor{alpha}-Induced Apoptosis Endocrinology, August 1, 2008; 149(8): 3789 - 3798. [Abstract] [Full Text] [PDF]

				R. S. Freedman, A. P. Kudelka, J. J. Kavanagh, C. Verschraegen, C. L. Edwards, M. Nash, L. Levy, E. N. Atkinson, H.-Z. Zhang, B. Melichar, et al. Clinical and Biological Effects of Intraperitoneal Injections of Recombinant Interferon-{{gamma}} and Recombinant Interleukin 2 with or without Tumor-infiltrating Lymphocytes in Patients with Ovarian or Peritoneal Carcinoma Clin. Cancer Res., June 1, 2000; 6(6): 2268 - 2278. [Abstract] [Full Text]